Associations of Leptin Receptor and Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms with Polycystic Ovary Syndrome

2019 ◽  
Vol 75 (3) ◽  
pp. 197-197
Author(s):  
Beuy Joob ◽  
Viroj Wiwanitkit
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Leptin Receptor ◽  
Polycystic Ovary ◽  
Peroxisome Proliferator ◽  
Ovary Syndrome ◽  
Peroxisome Proliferator Activated Receptor

Associations of Leptin Receptor and Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms with Polycystic Ovary Syndrome: A Meta-Analysis

2019 ◽  
Vol 75 (1) ◽  
pp. 1-8
Author(s):  
Jialang Liang ◽  
Jiarong Lan ◽  
Min Li ◽  
Fang Wang
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Leptin Receptor ◽  
Genetic Model ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Peroxisome Proliferator ◽  
Ovary Syndrome ◽  
Peroxisome Proliferator Activated Receptor ◽  
Subgroup Analyses ◽  
The Relationship

Background: Previous studies on associations of leptin receptor (LEPR) and peroxisome proliferator-activated receptor gamma (PPARG) polymorphisms with polycystic ovary syndrome (PCOS) yielded conflicting results. Objectives: In this meta-analysis, we aimed to better analyze the relationship between LEPR/PPARG polymorphisms and PCOS in a larger pooled population. Methods: We performed a systematic search of PubMed, Web of Science, Embase and CNKI. We calculated pooled ORs and 95% CIs to estimate associations between LEPR/PPARG polymorphisms and PCOS. Results: Totally, 33 eligible studies were included. A significant association with susceptibility to PCOS was observed for LEPR rs1137101 polymorphism under recessive genetic model (p = 0.002, OR 1.88, 95% CI 1.26–2.78, I2 = 42%) and for PPARG rs1801282 polymorphism under dominant (p = 0.007, OR 1.20, 95% CI 1.05–1.36, I2 = 49%), overdominant (p = 0.02, OR 0.85, 95% CI 0.74–0.97, I2 = 48%), and allele (p = 0.006, OR 1.18, 95% CI 1.05–1.33, I2 = 47%) genetic models in overall population. Further subgroup analyses by ethnicity revealed that LEPR rs1137101 and PPARG rs3856806 polymorphisms were both significantly associated with susceptibility to PCOS in Asians. No any positive results were detected in overall and subgroup analyses. Conclusions: Our meta-analysis suggested that LEPR rs1137101, PPARG rs1801282, and rs3856806 polymorphisms were all significantly associated with individual susceptibility to PCOS in certain populations.

scholarly journals Association of the Pro12Ala Polymorphism with the Metabolic Parameters in Women with Polycystic Ovary Syndrome

2017 ◽  
Vol 5 (3) ◽  
pp. 275-280 ◽  
Author(s):  
Moushira Zaki ◽  
Naglaa Hassan ◽  
Hala T. El-Bassyouni ◽  
Sanaa Kamal ◽  
Walaa Basha ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Fasting Blood Glucose ◽  
Metabolic Parameters ◽  
Peroxisome Proliferator ◽  
Pro12ala Polymorphism ◽  
Ovary Syndrome ◽  
Metabolic Complications ◽  
Peroxisome Proliferator Activated Receptor ◽  
Significant Difference

AIM: To investigate the association of peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala polymorphism with polycystic ovary syndrome (PCOS) and its effect on the metabolic parameters in PCOS women.METHODS: The study used PCR to identify the presence of the PPARG Pro12Ala polymorphism in 100 PCOS women and 120 age-matched healthy women. All participants were subjected to anthropometry, biochemical and metabolic evaluation.RESULTS: Significant difference in the genotypes distributions of PPARG Pro12Ala polymorphism was observed among PCOS women and controls (p = 0.03). The frequency of the polymorphic allele Ala was significantly higher in PCOS cases than that in the controls (OR = 2.01, p = 0.01). The carries of the variant allele Ala in PCOS women showed significant higher values in body mass index (BMI), systolic and diastolic blood pressure, waist circumference, waist to hip ratio, sum of skin folds, fasting blood glucose, fasting blood insulin, HOMA-IR, fasting triglycerides, total cholesterol and low-density lipoprotein than non-carriers.CONCLUSION: The PPARG Pro12Ala polymorphism might contribute to the risk of PCOS and abnormal metabolic parameters and could be considered as a biomarker for early diagnosis and clinic prediction of metabolic complications.

Sign in / Sign up

Export Citation Format

Share Document